bcrp - publications

Predict more bcrp - ligand interactions now!

1. Oral Oncol. 2012 Apr 21. [Epub ahead of print]

Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral
cancer development.

Feng JQ, Mi JG, Wu L, Ma LW, Shi LJ, Yang X, Liu W, Zhang CP, Zhou ZT.

Department of Preventive Dentistry, Shanghai Municipal Hospital for Oral Health,
Shanghai, China; Shanghai Key Laboratory of Stomatology, Department of Oral
Mucosal Diseases, Ninth People's Hospital, Shanghai Jiao Tong University School
of Medicine (SJTU-SM), Shanghai, China.

Oral erythroplakia (OE) is a notoriously aggressive oral premalignant lesion with
a high tendency to oral cancer development, but it's biological behavior is
largely unknown. The objective of the current study was to determine podoplanin
and ABCG2 immunoexpression in OE and both correlation to malignant transformation
of OE. In a retrospective follow-up study, the expression patterns of podoplanin
and ABCG2 were determined using immunohistochemistry in samples from 34 patients
with OE, including patients with untransformed lesions (n=17) and patients with
malignant transformed lesions (n=17). Podoplanin and ABCG2 expression was
observed in 15 (44.1%) and 21 (61.8%) of 34 patients, respectively. Multivariate
analysis revealed that podoplanin and ABCG2 expression was associated with
6.31-fold (95% confidence interval [CI], 1.02-38.92; P=0.047) and 14.39-fold (95%
CI, 2.02-102.29; P=0.008) increased the risk of transformation, respectively.
Point prevalence analysis revealed that 90.9% (95% CI, 70.7-100) of the patient
with both podoplanin and ABCG2 positivity developed oral cancer. Collectively,
our data indicated that the expression patterns of podoplanin and ABCG2 in OE
were associated with oral cancer development, suggesting that podoplanin and
ABCG2 may be valuable predictors for evaluating oral cancer risk.

Crown Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

PMID: 22525603 [PubMed - as supplied by publisher]